From Wikipedia, the free encyclopedia

Complement 3 (C3) through its interaction with factors B and D ( adipsin) generates C3a. In the human body, C3a is rapidly cleaved by carboxypeptidase B or carbxyopeptidase N, that remove the carboxyl-terminal arginine to generate C3adesArg. [1] Thus, most of plasmatic C3a is present in C3adesArg form. C3adesArg is more commonly named ASP or acylation-stimulating-protein due to its marked stimulating action on triacylglycerol synthesis in human adipocytes and skin fibroblasts. [2] ASP is also known for its augmentation of glucose transport and inhibiting action on hormone-sensitive lipase. Because of these actions, it is linked to the pathogenesis of obesity, [3] having been demonstrated to be present at increased levels in patients with obesity, [4] diabetes mellitus type 2 [5] and coronary artery disease. [6]

ASP lis a ligand for C5L2, a G-protein-coupled receptor. [7]

The view of C3a/C3adesArg as an acylation stimulating activity is not universally accepted. The evidence is discussed in a recent review. [8]

References

  1. ^ Baldo et al. 1993, pp. 1543–1547
  2. ^ Cianflone et al., pp. 426–430
  3. ^ ( Sniderman, Maslowska & Cianflone 2000, pp. 291–296)
  4. ^ Maslowska et al. 1999, pp. 679–686
  5. ^ Koistinen et al. 2001, pp. 1034–1039
  6. ^ Cianflone et al. 1997, pp. 1239–1244
  7. ^ Cui et al. 2009, pp. 3207–3217
  8. ^ Klos A, Wende E, Wareham KJ, Monk PN (2013). "International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors". Pharmacol. Rev. 65 (1): 500–43. doi: 10.1124/pr.111.005223. PMID  23383423.

Further reading

From Wikipedia, the free encyclopedia

Complement 3 (C3) through its interaction with factors B and D ( adipsin) generates C3a. In the human body, C3a is rapidly cleaved by carboxypeptidase B or carbxyopeptidase N, that remove the carboxyl-terminal arginine to generate C3adesArg. [1] Thus, most of plasmatic C3a is present in C3adesArg form. C3adesArg is more commonly named ASP or acylation-stimulating-protein due to its marked stimulating action on triacylglycerol synthesis in human adipocytes and skin fibroblasts. [2] ASP is also known for its augmentation of glucose transport and inhibiting action on hormone-sensitive lipase. Because of these actions, it is linked to the pathogenesis of obesity, [3] having been demonstrated to be present at increased levels in patients with obesity, [4] diabetes mellitus type 2 [5] and coronary artery disease. [6]

ASP lis a ligand for C5L2, a G-protein-coupled receptor. [7]

The view of C3a/C3adesArg as an acylation stimulating activity is not universally accepted. The evidence is discussed in a recent review. [8]

References

  1. ^ Baldo et al. 1993, pp. 1543–1547
  2. ^ Cianflone et al., pp. 426–430
  3. ^ ( Sniderman, Maslowska & Cianflone 2000, pp. 291–296)
  4. ^ Maslowska et al. 1999, pp. 679–686
  5. ^ Koistinen et al. 2001, pp. 1034–1039
  6. ^ Cianflone et al. 1997, pp. 1239–1244
  7. ^ Cui et al. 2009, pp. 3207–3217
  8. ^ Klos A, Wende E, Wareham KJ, Monk PN (2013). "International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors". Pharmacol. Rev. 65 (1): 500–43. doi: 10.1124/pr.111.005223. PMID  23383423.

Further reading


Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook